CRISPR Therapeutics CEO talks winning FDA approval for sickle cell anemia treatment
Samarth Kulkarni, CRISPR Therapeutics CEO, joins 'Closing Bell Overtime' to talk winning FDA approval in the U.S. for sickle cell treatment in partnership with Vertex.
▶︎
Samarth Kulkarni, CEO, CRISPR Therapeutics
▶︎
CRISPR Therapeutics (CRSP STOCK): HUGE INSIDER BUY! 100% UPSIDE?
▶︎
CRISPR the emergence of TIGR systems Rewriting DNA
▶︎
Teen is one of the first ever to get his genes edited. Why he says the process is 'cool and freaky'
▶︎
GMP requirements for cell and gene therapy institutions-20201112 0600-1
▶︎
CRISPR-based gene editing revolutionized medicine—what's next?
▶︎
David Liu: A Master Class on the Future of Genome Editing
▶︎
Is CRISPR Therapeutics Stock Worth the Hype?
▶︎
Understanding CRISPR-Cas9
▶︎
76th Cellular, Tissue, and Gene Therapies Advisory Committee
▶︎
CRISPR's Next Advance Is Bigger Than You Think | Jennifer Doudna | TED
▶︎
323 - CRISPR and the future of gene editing: scientific advances, genetic therapies, & more
▶︎
FDA Approves First Crispr Treatment for Sickle Cell Disease
▶︎
An Outlook on Biotechnology with Sam Kulkarni, CEO CRISPR Therapeutics
▶︎
The First CRISPR Gene Therapy Is Here
▶︎
What is CRISPR?
▶︎
Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed
▶︎
Mechanism explained- CRISPR Drug for Sickle Cell Anemia (Casgevy)
▶︎
Why AI Hasn't Cured Anything...Yet, According to Jennifer Doudna | The Circuit
▶︎